Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263978 | 1.00 | HTR3A (0.53) | HTR3ASLC6A2SLC6A3PRCPCHRNA7 | |
| Hydrochloric Acid SCHEMBL1673491 | 0.98 | HTR3A (0.52) | HTR3ASLC6A2SLC6A3PRCPCHRNA7 | |
| Hydrochloric Acid SCHEMBL2031988 | 0.98 | HTR3A (0.52) | HTR3ASLC6A2SLC6A3PRCPCHRNA7 | |
| Hydrochloric Acid SCHEMBL1673492 | 0.98 | HTR3A (0.52) | HTR3ASLC6A2SLC6A3PRCPCHRNA7 | |
| SCHEMBL27292102 | 0.91 | HTR3A (0.46) | HTR3ASLC6A2SLC6A3CHRNA7 | |
| SCHEMBL1069753 | 0.83 | SLC6A3 (0.48) | HTR3ASLC6A2SLC6A3PRCPCHRNA7 | |
| SCHEMBL12537047 | 0.82 | HTR3A (0.52) | HTR3ASLC6A2SLC6A3PRCPCHRNA7 | |
| SCHEMBL4467879 | 0.82 | HTR3A (0.46) | HTR3ASLC6A2SLC6A3PRCPCHRNA7 | |
| SCHEMBL552751 | 0.80 | MAPT (0.43) | — | |
| SCHEMBL10563871 | 0.80 | PARP1 (0.35) | HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273883-B2 | Method for producing optically active 2-arylpiperazine derivative | KANEKA CORPORATION (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2308854-A1 | 2,3,6-trisubstituted-4-pyrimidone derivatives | Sanofi-Aventis (FR) | 2011-04-13 | — | — | EP | disclosed |
| EP-2305651-A1 | 2,3,6-trisubstituted-4-pyrimidone derivatives | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-04-06 | — | — | EP | disclosed |
| CN-1764650-B | 2, 3, 6-trisubstituted-4-pyrimidone derivatives | MITSUBISHI PHARMA CORP | 2010-06-16 | — | — | CN | disclosed |
| US-20100087643-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-ARYLPIPERAZINE DERIVATIVE | KANEKA CORPORATION (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-2119709-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-ARYLPIPERAZINE DERIVATIVE | Kaneka Corporation (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20060252768-A1 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | SANOFI (FR) | 2006-11-09 | — | — | US | disclosed |
| CN-1764650-A | 2, 3, 6-trisubstituted-4-pyrimidone derivatives | MITSUBISHI PHARMA CORP (JP) | 2006-04-26 | — | — | CN | disclosed |
| EP-1608630-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004085408-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087643-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-ARYLPIPERAZINE DERIVATIVE | CYP2W1, AGPS, DHPS | HTR3A 928/4885SLC6A2 1246/4885SLC6A3 1349/4885 |
| US-20060252768-A1 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | PSEN1, PSEN2, MAPT | HTR3A 665/4885SLC6A2 628/4885SLC6A3 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.